Marksans Pharma Limited has released the transcript of its investor and analyst meet held on May 27, 2026, to discuss the Q4 and full-year FY26 audited financial results. The company reported crossing INR3,000 crores in net income for the first time in FY26, with the highest ever profitability. Revenue for FY26 reached INR2,951 crores, a 12.5% increase year-on-year, driven by strong performance in North America (INR1,533 crores, up 24%) and the UK & EU markets (INR1,015 crores). Gross margin improved to 56.7% and EBITDA margin stood at 20.4% for FY26. For Q4 FY26, operating revenue was INR856 crores (up 20.8% YoY), with EBITDA at INR195 crores (up 54% YoY) and EBITDA margin at 22.8%. Profit after tax for Q4 FY26 was INR149 crores, a 64.3% increase YoY. The company declared a final dividend of INR0.90 per equity share for FY26. Management discussed strategies for geographical diversification, portfolio expansion, and margin improvement, while also addressing concerns about raw material cost inflation and its potential impact on Q1 FY27. The company maintains a strong balance sheet with INR990 crores in cash and cash equivalents as of March 31, 2026. During the call, management highlighted the expansion into new markets like Germany, Canada, and Ireland, and strengthening presence in Australia through branded prescription generics. They also discussed plans to file over 200 products in the UK market in the next four years and aim to double revenue in the next 3 to 5 years, with a target of INR4,000 crores by FY28. The company is exploring M&A opportunities and is in due diligence for one target. Guidance for FY27 EBITDA margins is expected to be around 20-21%, with top-line growth projected at 15-20%. The Teva facility is operating at close to 50% capacity, with scope for further utilization and planned capex for new dosage forms.
